A Phase 2 interventional study of QBS72S in Brain Metastases, Breast Cancer and Lung Cancer, sponsored by Melanie Hayden Gephart. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Melanie Hayden Gephart · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,447 studies in Brain Neoplasms with a site in United States — 233 open to participants now, 355 under way, 18 of them phase 3. Brain Neoplasms · United States.
Among the 1,447 studies in Brain Neoplasms with a site in United States, this one is the 730th largest by enrollment of the 1,192 interventional ones that give a count, is one of 59 that started in 2022, is one of 383 in phase 2, reaches primary completion later than 24 of the 353 other live ones, and was the 1,221st registered.
2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.
Browse Brain Neoplasms studies →233 of the 1,447 studies in Brain Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Brian J.Gill · Sites in United States
Ages 22–65
Stanford University · Sites in United States
Ages 6 mo–25 yrs
University of California, San Francisco · Sites in United States
Ages 18+
Beijing Inno Medicine Co., Ltd. · Sites in United States, China
Ages 18–70
University of Florida · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,447 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 554 · Phase 2 522 · Phase 3 72 · Phase 4 18
First in 1979; this study’s year is marked. 59 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 40 across 1,838 interventional studies indexed under Brain Neoplasms.
Median enrollment 30 across the 1,192 interventional studies, 76 across the 191 observational. Of the 994 that completed or were terminated, 355 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
221 of 1,447 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Melanie Hayden Gephart as lead sponsor.
Melanie Hayden Gephart has 1 study filed under Brain Neoplasms — fewer than ten, so there is no comparison to draw.
140 of the studies in Brain Neoplasms with a site in United States that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00978458Phase 3Eastern Cooperative Oncology GroupRadiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma | 2026-12-31 |
| NCT03741673Phase 3M.D. Anderson Cancer CenterPre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases | 2027-01-31 |
| NCT05438212Phase 3NRG OncologyComparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases | 2027-03-16 |
| NCT05271240Phase 3Northwell HealthRepeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM | 2027-04-01 |
| NCT00950001Phase 3M.D. Anderson Cancer CenterStereotactic Radiosurgery Compared to Observation in Treating Patients With Brain Metastases | 2027-04-30 |
Add all 140 to your calendar (.ics) → With an account.
Among the 1,447 studies in Brain Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is to evaluate the efficacy and safety of QBS72S in participants with advanced, relapsed, metastatic cancer with CNS involvement
Primary Objective
1. Test of the preliminary efficacy of the intracranial anti tumor activity of QBS72S through overall response rate (ORR) in Cohort 1 (Stages 1+2).
Secondary Objectives
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
One of the following:
One of the following:
LMD must receive either:
i. a brain MRI with contrast that supports the presence of LMD, or ii. a CSF cytology test that is either positive for or suspicious for . The presence of parenchymal brain metastases does not exclude these participants from Cohort 2.
a. Cohort 3: A participant with LMD from any primary cancer site must receive either: i. a brain MRI with contrast that supports the presence of LMD, or ii. a CSF cytology test that is either positive for or suspicious for malignancy. The presence of parenchymal brain metastases does not exclude these participants from Cohort 3.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants in Cohort 1 Stage 1 will receive QBS72S IV injections once monthly until disease progression.
Drug: QBS72S
All participants in Cohort 1 Stage 2 will receive QBS72S IV injections once monthly until disease progression. This cohort never opened to enrollment
Drug: QBS72S
All participants in Cohort 3 will receive QBS72S IV injections once monthly until disease progression.
Drug: QBS72S
All participants in Cohort 3 will receive QBS72S IV injections once monthly until disease progression.
Drug: QBS72S
QBS72S 18mg/m2 injection given intravenous once a month.
Also known as: QBS10072S
Overall Response Against Intracranial Tumor Lesions, Cohort 1- Stage 1
The overall response against the target intracranial tumor lesions in Cohort 1-Stage 1 participants was assessed by according to the modified Response Assessment in Neuro-oncology for Brain Metastases (mRANO-BM) and RECIST 1.1 response criteria. Clinical response means either a complete response (CR) or a partial response (CR). CR is defined as disappearance of tumor lesions, and PR is defined as ≥ 30% reduction in diameter of tumor lesions. The outcome is reported the number of Cohort 1- Stage 1 participants who achieved a CR or PR within 6 months from the start of treatment.
Time frame: 6 months
Progression-free Survival (PFS), Cohort 1-Stage 1
Progression-free Survival (PFS) means to remain alive without tumor progression, assessed as a ≥ 25% increase in tumor diameter. The outcome is reported as the number of participants in Cohort 1- Stage 1 who remained alive at 2 months without tumor progression.
Time frame: 2 months
Overall Survival (OS), Cohort 1- Stage 1
Overall survival (OS) refers to remaining alive at the time of the assessment. The outcome is reported as the number of participants in Cohort 1- Stage 1 who remained alive at 2 months.
Time frame: 2 months
Duration of Response (DoR), Cohort 1 - Stage 1
Duration of Response (DoR) referred to the length of time that a clinical response was maintained in Cohort 1 (Stages 1+2) participants. Clinical response means either a complete response (CR) or a partial response (PR). CR was defined as disappearance of tumor lesions, and PR was defined as ≥30% reduction in diameter of tumor lesions. The outcome was assessed at 6 months and reported as median DoR with standard deviation for Cohort 1-Stage 1 participants who achieved a clinical response. If no participants achieved a clinical response, DoR was not evaluable.
Time frame: 6 months
Related Adverse Events (AEs)
Toxicity refers to drug-related adverse events (AEs). The outcome is reported as the number of related AEs that were serious per 21CFR§312.32 or non-serious, and by severity (mild, moderate, severe, life-threatening, or fatal), numbers without dispersion. Life-threatening events will only be those that are clinically life-threatening, and not merely a laboratory value without significant clinical symptoms.
Time frame: 30 days following the last administration of study drug, up to 1 year
| Milestone | Patients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1) | Patients With Breast Cancer Leptomeningeal Disease (Cohort 2) | Patients With Any Primary Cancer Leptomeningeal Disease (Cohort 3) |
|---|---|---|---|
| Started | 6 | 10 | 5 |
| Completed | 6 | 10 | 5 |
| Not completed | 0 | 0 | 0 |
The overall response against the target intracranial tumor lesions in Cohort 1-Stage 1 participants was assessed by according to the modified Response Assessment in Neuro-oncology for Brain Metastases (mRANO-BM) and RECIST 1.1 response criteria. Clinical response means either a complete response (CR) or a partial response (CR). CR is defined as disappearance of tumor lesions, and PR is defined as ≥ 30% reduction in diameter of tumor lesions. The outcome is reported the number of Cohort 1- Stage 1 participants who achieved a CR or PR within 6 months from the start of treatment.
| Participants | Patients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1) |
|---|---|
| Complete Response (CR) | 0 |
| Partial Response (CR) | 0 |
Progression-free Survival (PFS) means to remain alive without tumor progression, assessed as a ≥ 25% increase in tumor diameter. The outcome is reported as the number of participants in Cohort 1- Stage 1 who remained alive at 2 months without tumor progression.
| Participants | Patients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1) |
|---|---|
| Progression-free Survival (PFS), Cohort 1-Stage 1 | 0 |
Overall survival (OS) refers to remaining alive at the time of the assessment. The outcome is reported as the number of participants in Cohort 1- Stage 1 who remained alive at 2 months.
| Participants | Patients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1) |
|---|---|
| Overall Survival (OS), Cohort 1- Stage 1 | 1 |
Duration of Response (DoR) referred to the length of time that a clinical response was maintained in Cohort 1 (Stages 1+2) participants. Clinical response means either a complete response (CR) or a partial response (PR). CR was defined as disappearance of tumor lesions, and PR was defined as ≥30% reduction in diameter of tumor lesions. The outcome was assessed at 6 months and reported as median DoR with standard deviation for Cohort 1-Stage 1 participants who achieved a clinical response. If no participants achieved a clinical response, DoR was not evaluable.
| months | Patients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1) |
|---|---|
| Duration of Response (DoR), Cohort 1 - Stage 1 | 0 ± 0 |
Toxicity refers to drug-related adverse events (AEs). The outcome is reported as the number of related AEs that were serious per 21CFR§312.32 or non-serious, and by severity (mild, moderate, severe, life-threatening, or fatal), numbers without dispersion. Life-threatening events will only be those that are clinically life-threatening, and not merely a laboratory value without significant clinical symptoms.
| Events | Patients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1) | Patients With Breast Cancer Leptomeningeal Disease (Cohort 2) | Patients With Any Primary Cancer Leptomeningeal Disease (Cohort 3) |
|---|---|---|---|
| Mild (Grade 1) | 32 | 64 | 9 |
| Moderate (Grade 2) | 9 | 30 | 9 |
| Severe (Grade 3) | 5 | 24 | 11 |
| Life-threatening (Grade 4) | 2 | 3 | 5 |
| Fatal (Grade 5) | 0 | 0 | 0 |
Collected over 30 days following the last administration of study drug, up to 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Patients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1) | 0/6 (0%) | 3/6 (50%) | 6/6 (100%) |
| Patients With Breast Cancer Leptomeningeal Disease (Cohort 2) | 0/10 (0%) | 5/10 (50%) | 10/10 (100%) |
| Patients With Any Primary Cancer Leptomeningeal Disease (Cohort 3) | 0/5 (0%) | 4/5 (80%) | 5/5 (100%) |
| Event | Patients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1) | Patients With Breast Cancer Leptomeningeal Disease (Cohort 2) | Patients With Any Primary Cancer Leptomeningeal Disease (Cohort 3) |
|---|---|---|---|
| SeizureNervous System Disorders | 0/6 | 2/10 | 2/5 |
| NauseaGastrointestinal Disorders | 0/6 | 0/10 | 2/5 |
| HeadacheNervous System Disorders | 0/6 | 0/10 | 2/5 |
| DizzinessNervous System Disorders | 0/6 | 1/10 | 1/5 |
| Edema, cerebralNervous system disorders | 0/6 | 2/10 | 0/5 |
| HypoxiaRespiratory, Thoracic and Mediastinal Disorders | 1/6 | 1/10 | 1/5 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/6 | 0/10 | 1/5 |
| Lung infectionInfections and infestations | 0/6 | 0/10 | 1/5 |
| ColitisGastrointestinal Disorders | 1/6 | 0/10 | 0/5 |
| Back painMusculoskeletal and connective tissue disorders | 1/6 | 0/10 | 0/5 |
| Event | Patients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1) | Patients With Breast Cancer Leptomeningeal Disease (Cohort 2) | Patients With Any Primary Cancer Leptomeningeal Disease (Cohort 3) |
|---|---|---|---|
| Lymphocyte count decreasedInvestigations | 5/6 | 6/10 | 1/5 |
| White blood cell decreasedInvestigations | 5/6 | 7/10 | 2/5 |
| Platelet count decreasedInvestigations | 4/6 | 7/10 | 1/5 |
| NauseaGastrointestinal Disorders | 4/6 | 5/10 | 1/5 |
| FallInjury, poisoning and procedural complications | 1/6 | 5/10 | 1/5 |
| Absolute lymphocyte count decreasedInvestigations | 3/6 | 2/10 | 2/5 |
| Absolute neutrophil count decreasedInvestigations | 3/6 | 5/10 | 0/5 |
| VomitingGastrointestinal Disorders | 0/6 | 3/10 | 2/5 |
| FatigueGeneral Disorders and Administration Site Conditions | 2/6 | 4/10 | 0/5 |
| HyperuricemiaMetabolism and Nutrition Disorders | 0/6 | 0/10 | 2/5 |
| Age, Categorical(Participants) | Patients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1) | Patients With Breast Cancer Leptomeningeal Disease (Cohort 2) | Patients With Any Primary Cancer Leptomeningeal Disease (Cohort 3) | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 9 | 5 | 18 |
| >=65 years | 2 | 1 | 0 | 3 |
| Sex: Female, Male(Participants) | Patients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1) | Patients With Breast Cancer Leptomeningeal Disease (Cohort 2) | Patients With Any Primary Cancer Leptomeningeal Disease (Cohort 3) | Total |
|---|---|---|---|---|
| Female | 6 | 10 | 4 | 20 |
| Male | 0 | 0 | 1 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Patients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1) | Patients With Breast Cancer Leptomeningeal Disease (Cohort 2) | Patients With Any Primary Cancer Leptomeningeal Disease (Cohort 3) | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 0 | 2 |
| Not Hispanic or Latino | 4 | 10 | 5 | 19 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Patients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1) | Patients With Breast Cancer Leptomeningeal Disease (Cohort 2) | Patients With Any Primary Cancer Leptomeningeal Disease (Cohort 3) | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 1 | 1 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 3 | 6 | 1 | 10 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 3 | 1 | 5 |
| Region of Enrollment(participants) | Patients With Breast Cancer Parenchymal Brain Metastasis (Cohort 1, Stage 1) | Patients With Breast Cancer Leptomeningeal Disease (Cohort 2) | Patients With Any Primary Cancer Leptomeningeal Disease (Cohort 3) | Total |
|---|---|---|---|---|
| United States | 6 | 10 | 5 | 21 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2022 to primary completion in Jun 2025, 34 months.
Results were first posted in Oct 2026, 1 year 4 months after primary completion.
Of 208 non-industry phase 2 interventional studies under Brain Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 100. This study's 34 months is below that.
Counting every sponsor, half of 252 studies reached it within 61 months; a quarter within 38 and three quarters within 98.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cytotoxic Agent-LAT1 Substrate QBS10072S